Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

Author: Vandana Singh | August 23, 2021 09:08am

Pfizer Inc (NYSE:PFE) has agreed to acquire Trillium Therapeutics Inc (NASDAQ:TRIL) for $18.50 per share, equivalent to an implied equity value of $2.26 billion.
The offer price represents a 118% premium to the 60-day weighted average price for Trillium.
Trillium's portfolio includes biologics include immuno-oncology product candidates.
Its two lead molecules, TTI-622 and TTI-621, block the signal-regulatory protein α (SIRPα)–CD47 axis, emerging as a key immune checkpoint in hematological malignancies.
TTI-622 and TTI-621 are SIRPα-Fc fusion proteins currently in Phase 1b/2 development across several indications, focusing on hematological malignancies.
Related Content: Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies.
Pfizer will conduct a webcast at 10:00 a.m. ET today.
Price Action: TRIL stock soared 191.50% at $17.75, and PFE stock is up 2.94% at $50.15 during the premarket session on the last check Monday.

Posted In: PFE TRIL